By targeting the MLL-AF9-DOT1L interaction, DOT1L recruitment is blocked, leading to inhibition of the growth of MLL-AF9-driven leukemia cells, selective downregulation of MLL-target gene expression by decreasing H3K79 methylation, followed by differentiation. Here, KMT2A is linked to leukemia.